CagriSema
Cagrilintide/semaglutide fixed-dose combination
Clinical trials are ongoing or recently completed. Final approval has not been granted.
An investigational once-weekly combination injection that pairs two appetite-controlling medications to produce powerful weight loss. In a major clinical trial, people lost an average of 20% of their body weight over about 16 months, compared to just 3% with placebo (an inactive comparison treatment). This medication is not yet approved.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
In REDEFINE 1, gastrointestinal adverse events affected 79.6% of the CagriSema group vs 39.9% of placebo, including nausea, vomiting, diarrhea, constipation, and abdominal pain. Most were transient and mild-to-moderate in severity (PMID 40544433). In REDEFINE 2, GI AEs affected 72.5% of the CagriSema group vs 34.4% of placebo (PMID 40544432). In the Phase 2 trial, AEs were reported by 68% of CagriSema participants, 71% semaglutide, and 80% cagrilintide; no level 2 or 3 hypoglycemia or fatal AEs were reported (PMID 37364590). A meta-analysis of 4 RCTs (N=4419) found GI AEs were more frequent with CagriSema vs controls (RR 1.32) (PMID 41759565). Vomiting was significantly higher with CagriSema vs semaglutide monotherapy in a separate meta-analysis of 3 RCTs (N=430) (PMID 39676787). The cagrilintide component showed no clinically relevant QTcF prolongation at supratherapeutic doses (4.5 mg) in a dedicated cardiac safety study in healthy participants (PMID 39279639).
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-12]